Calliditas Therapeutics AB (publ) - Special Call Transcript
Hello, and welcome to Calliditas press conference. (Operator Instructions) Today, I'm pleased to present CEO, Renee Lucander; and CMO, Richard Philipson. Speakers, please begin.
()-
Thank you. So I'm delighted to welcome you to this presentation of the Phase III Part A top line data readout of the trial NefIgArd.
If you turn to Page 3, I'm just going to give a very brief summary before I hand over to our CMO to take you through the data. Just to remind you, the company is listed both in Sweden and the U.S. on OMX and on Nasdaq. We listed in Sweden in 2018 and recently listed on Nasdaq in the U.S. in June of this year. Our lead candidate, Nefecon, is a novel investigational treatment for IgAN, and that locally treats this disease with a view to be disease modifying. And we do this by locally treating a big presumed origin of this disease.
In terms of the company's position, we are now positioned clearly to be the first potentially
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
